| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Claire Parker, Bethany Marie Woo. At the Forefront: Social Workers' Role in Psilocybin Treatment for Depression and Substance Misuse. Social work. 2024-05-02. PMID:38697188. |
at the forefront: social workers' role in psilocybin treatment for depression and substance misuse. |
2024-05-02 |
2024-05-05 |
Not clear |
| Riccardo De Giorgi, Roger Ed. Psilocybin for depression. BMJ (Clinical research ed.). vol 385. 2024-05-01. PMID:38692675. |
psilocybin for depression. |
2024-05-01 |
2024-05-04 |
Not clear |
| Athina-Marina Metaxa, Mike Clark. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ (Clinical research ed.). vol 385. 2024-05-01. PMID:38692686. |
efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. |
2024-05-01 |
2024-05-04 |
Not clear |
| K Conn, L K Milton, K Huang, H Munguba, J Ruuska, M B Lemus, E Greaves, J Homman-Ludiye, B J Oldfield, C J Fold. Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms. Molecular psychiatry. 2024-04-27. PMID:38678087. |
psilocybin has shown promise for alleviating symptoms of depression and is currently in clinical trials for the treatment of anorexia nervosa (an), a condition that is characterised by persistent cognitive inflexibility. |
2024-04-27 |
2024-04-30 |
rat |
| Ram Harari, Ipsita Chatterjee, Dmitriy Getselter, Evan Elliot. Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor. iScience. vol 27. issue 5. 2024-04-26. PMID:38660396. |
psilocybin has been proposed as a treatment for depression and anxiety but sometimes induces anxiety in humans. |
2024-04-26 |
2024-04-28 |
mouse |
| Gail A Edelsohn, Dominic Sist. Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment. Perspectives in biology and medicine. vol 66. issue 1. 2024-04-25. PMID:38662012. |
mdma and psilocybin administered with psychotherapy have received fda designation as "breakthrough therapies" for post-traumatic stress disorder (ptsd) and treatment-resistant depression (trd) respectively. |
2024-04-25 |
2024-04-28 |
Not clear |
| Jordan Sloshower, Richard J Zeifman, Jeffrey Guss, Robert Krause, Hamideh Safi-Aghdam, Surbhi Pathania, Brian Pittman, Deepak Cyril D'Souz. Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial. Scientific reports. vol 14. issue 1. 2024-04-17. PMID:38632313. |
additionally, improvements in psychological flexibility and experiential acceptance were strongly associated with reductions in depression severity following psilocybin. |
2024-04-17 |
2024-04-20 |
Not clear |
| Sheng-Min Wang, Sunghwan Kim, Won-Seok Choi, Hyun Kook Lim, Young Sup Woo, Chi-Un Pae, Won-Myong Bah. Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 22. issue 2. 2024-04-16. PMID:38627070. |
fda designated psilocybin as a "breakthrough therapy" for the treatment of treatment-resistant depression (trd) in 2018. |
2024-04-16 |
2024-04-19 |
Not clear |
| Sheng-Min Wang, Sunghwan Kim, Won-Seok Choi, Hyun Kook Lim, Young Sup Woo, Chi-Un Pae, Won-Myong Bah. Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 22. issue 2. 2024-04-16. PMID:38627070. |
this paper provided a review of psilocybin's potential role in treatment of depression by focusing on published clinical trials. |
2024-04-16 |
2024-04-19 |
Not clear |
| Akhila Yerubandi, Jennifer E Thomas, N M Mahmudul Alam Bhuiya, Catherine Harrington, Lorenzo Villa Zapata, Joshua Caballer. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA network open. vol 7. issue 4. 2024-04-10. PMID:38598236. |
psilocybin has been studied in the treatment of depression and anxiety disorders. |
2024-04-10 |
2024-04-12 |
Not clear |
| Zarah R Haniff, Mariia Bocharova, Tim Mantingh, James J Rucker, Latha Velayudhan, David M Taylor, Allan H Young, Dag Aarsland, Anthony C Vernon, Sandrine Thure. Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. Pharmacology & therapeutics. 2024-04-07. PMID:38583670. |
the potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. |
2024-04-07 |
2024-04-10 |
Not clear |
| Zarah R Haniff, Mariia Bocharova, Tim Mantingh, James J Rucker, Latha Velayudhan, David M Taylor, Allan H Young, Dag Aarsland, Anthony C Vernon, Sandrine Thure. Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. Pharmacology & therapeutics. 2024-04-07. PMID:38583670. |
in this context, psilocybin, a serotonergic agonist with rapid-acting antidepressant properties has the potential to ameliorate intersecting pathophysiological processes relevant for both major depression and neurodegenerative diseases. |
2024-04-07 |
2024-04-10 |
Not clear |
| Zarah R Haniff, Mariia Bocharova, Tim Mantingh, James J Rucker, Latha Velayudhan, David M Taylor, Allan H Young, Dag Aarsland, Anthony C Vernon, Sandrine Thure. Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. Pharmacology & therapeutics. 2024-04-07. PMID:38583670. |
in this narrative review, we focus on the evidence base for the effects of psilocybin on adult hippocampal neurogenesis and microglial form and function; which may suggest that psilocybin has the potential to modulate multiple mechanisms of action, and may have implications in altering the progression from major depression to dementia in those at risk. |
2024-04-07 |
2024-04-10 |
Not clear |
| Evana López, Hampus Yngwe, Maria Beckman, Mikael Tiger, Fredrik Hieronymus, Johan Lundber. [Psychedelic psychiatry]. Lakartidningen. vol 121. 2024-04-04. PMID:38572715. |
this review focuses on the psychedelic compound psilocybin, a serotonin-2a-receptor agonist that has been seen to reduce depression and anxiety in patients after administration of only a single dose, with effects lasting several weeks. |
2024-04-04 |
2024-04-06 |
Not clear |
| Evana López, Hampus Yngwe, Maria Beckman, Mikael Tiger, Fredrik Hieronymus, Johan Lundber. [Psychedelic psychiatry]. Lakartidningen. vol 121. 2024-04-04. PMID:38572715. |
recent findings from phase ii studies suggest that psilocybin treatment for depression is safe and efficacious. |
2024-04-04 |
2024-04-06 |
Not clear |
| Gia Han Le, Sabrina Wong, Sebastian Badulescu, Hezekiah Au, Joshua D Di Vincenzo, Hartej Gill, Lee Phan, Taeho Greg Rhee, Roger Ho, Kayla M Teopiz, Angela T H Kwan, Joshua D Rosenblat, Rodrigo B Mansur, Roger S McIntyr. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. Journal of affective disorders. 2024-04-03. PMID:38570038. |
spectral signatures of psilocybin, lysergic acid diethylamide (lsd) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: a systematic review. |
2024-04-03 |
2024-04-06 |
human |
| Jesse Hudspeth, Kai Rogge, Sebastian Dörner, Maximilian Müll, Dirk Hoffmeister, Bernhard Rupp, Sebastiaan Werte. Methyl transfer in psilocybin biosynthesis. Nature communications. vol 15. issue 1. 2024-03-29. PMID:38548735. |
psilocybin, the natural hallucinogen produced by psilocybe ("magic") mushrooms, holds great promise for the treatment of depression and several other mental health conditions. |
2024-03-29 |
2024-03-31 |
Not clear |
| David Erritzoe, Tommaso Barba, Meg J Spriggs, Fernando E Rosas, David J Nutt, Robin Carhart-Harri. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. Journal of psychopharmacology (Oxford, England). 2024-03-23. PMID:38520045. |
effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. |
2024-03-23 |
2024-03-26 |
human |
| David Erritzoe, Tommaso Barba, Meg J Spriggs, Fernando E Rosas, David J Nutt, Robin Carhart-Harri. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. Journal of psychopharmacology (Oxford, England). 2024-03-23. PMID:38520045. |
there is growing evidence for the therapeutic effects of the psychedelic drug psilocybin for major depression. |
2024-03-23 |
2024-03-26 |
human |
| Jakub Vohryzek, Joana Cabral, Louis-David Lord, Henrique M Fernandes, Leor Roseman, David J Nutt, Robin L Carhart-Harris, Gustavo Deco, Morten L Kringelbac. Brain dynamics predictive of response to psilocybin for treatment-resistant depression. Brain communications. vol 6. issue 2. 2024-03-22. PMID:38515439. |
brain dynamics predictive of response to psilocybin for treatment-resistant depression. |
2024-03-22 |
2024-03-24 |
Not clear |